On heels of record-breaking Q2, Pfizer CEO Albert Bourla outlines plans to ‘go very big’ on BD
Pfizer CEO Albert Bourla uncorked some record-breaking Q2 numbers on Thursday, including the company’s highest-ever quarterly sales thanks to Comirnaty and Paxlovid, all while raising the full-year guidance. What’s he going to do with that cash?
“Go very big” on new deals, he said on the company’s Q2 call with investors.
“We’re leaving very few stones unturned when we look at opportunities,” chief business innovation officer Aamir Malik added. “We’re going to be very open to deal structures, and we’ve said before we’re also going to be agnostic to size.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.